| T9295 |
BLU-263
|
2505078-08-8
|
98%
|
|
|
BLU-263 is an investigational, potent, and selective oral small molecule inhibitor of KIT with sub-nanomolar potency against D816V-mutant KIT.
|
| T4320 |
Flumatinib
|
895519-90-1
|
98%
|
|
|
Flumatinib (HHGV678) is an orally bioavailable tyrosine kinase inhibitor flumatinib, with potential antineoplastic activity.
|
| T8544 |
Masitinib mesylate
|
1048007-93-7
|
98%
|
|
|
Masitinib mesylate (AB-1010 mesylate) is a selective and orally bioavailable c-Kit inhibitor (IC50 of 200 nM,540/800 nM,510 nM for human recombinant c-Kit;PDGFRα...
|
| T4315 |
Ki20227
|
623142-96-1
|
|
|
|
Ki-20227 is a specific c-Fms tyrosine kinase(CSF1R) inhibitor (IC50: 2 nM). It also has certain inhibitory against VEGFR2(IC50: 12 nM) and c-Kit/PDGFRβ(IC50: 451...
|
| T5409 |
AZD3229
|
2248003-60-1
|
|
|
|
AZD3229 is a potent pan-KIT mutant inhibitor for the treatment of gastrointestinal stromal tumors. It demonstrates potent single-digit nM growth inhibition acros...
|
| T3452 |
ISCK03
|
945526-43-2
|
|
|
|
ISCK03 is a selective SCF/c-Kit inhibitor.
|
| TQ0235 |
AC710
|
1351522-04-7
|
|
|
|
AC710 is a potent PDGFR inhibitor (Kds: 0.6, 1, 1.57, 1.3, 1 nM for FLT3, KIT, CSF1R, PDGFRα and PDGFRβ).
|
| T7104 |
Dovitinib lactate
|
692737-80-7
|
100%
|
|
|
Dovitinib lactate (TKI-258 lactate)(TKI258) lactate is a potent inhibitor of fibroblast growth factor receptor 3 (FGFR3) (IC50 :5 nM).
|
| T35570 |
Chiauranib
|
1256349-48-0
|
96.25%
|
|
|
Chiauranib is a multi-target inhibitor against tumor angiogenesis and exhibits potent anticancer effects. Chiauranib potently inhibits the angiogenesis-related k...
|
| T67847 |
Imatinib impurities3
|
404844-11-7
|
97.05%
|
|
|
Imatinib impurities3 is a protein kinases inhibitor with IC50 values of 6.95uM, 0.245uM, 0.139uM for ABL1 wt, KIT wt, PDGFRR wt, respectively.
|
| T5164 |
Cabozantinib hydrochloride
|
1817759-42-4
|
97.09%
|
|
|
Cabozantinib hydrochloride (XL184) is a potent pan-tyrosine kinases inhibitor that inhibits VEGFR2, c-Met, Kit, Axl, and Flt4 (IC50s: 0.035, 1.3, 4.6, 7 and 6 nM...
|
| T13178 |
Toceranib
|
356068-94-5
|
97.14%
|
|
|
Toceranib (PHA 291639E) phosphate is an orally active inhibitor of tyrosine kinase (RTK) receptor, and it potently inhibits PDGFR, VEGFR, and Kit(with Kis of 5 a...
|
| T10803 |
CHMFL-KIT-033
|
2351801-41-5
|
97.26%
|
|
|
CHMFL-KIT-033 is an effective and selective c-KIT inhibitor with an IC50 value of 45 nM for c-KIT T670I mutant in gastrointestinal stromal tumors.
|
| T1836 |
AZD2932
|
883986-34-3
|
97.71%
|
|
|
AZD2932 is a potent and multi-targeted kinase inhibitor VEGFR2, PDGFβ, Flt-3, and c-Kit.
|
| T7394 |
Toceranib Phosphate
|
874819-74-6
|
98%
|
|
|
Toceranib Phosphate (SU11654 phosphate), is a selective inhibitor of the tyrosine kinase activity of several members of the split kinase RTK family, including Fl...
|
| T10157 |
Regorafénib N-oxyde (M2)
|
835621-11-9
|
98.03%
|
|
|
Regorafénib N-oxyde M2 is an active metabolite of Regorafenib. Regorafenib is a multi-target inhibitor for VEGFR1/2/3, PDGFRβ, RET, Kit, and Raf-1 (IC50s: 13/4.2...
|
| T22349 |
JNJ-38158471
|
951151-97-6
|
98.04%
|
|
|
JNJ-38158471 (CS-2660), a highly selective, orally available, well tolerated VEGFR2 inhibitor with IC50 of 40 nM, inhibits closely related tyrosine kinases such ...
|
| T4332 |
C-Kit-IN-1
|
1225278-16-9
|
98.16%
|
|
|
c-Kit-IN-1 (DCC-2618) is an effective inhibitor of c-Met and c-Kit (IC50s<200 nM).
|
| T4053 |
AST 487
|
630124-46-8
|
98.17%
|
|
|
AST 487 (NVP-AST 487) is a RET kinase inhibitor, inhibiting RET autophosphorylation and activation of downstream effectors. It also can inhibit Flt-3.
|
| T41003 |
KG5
|
877874-85-6
|
98.2%
|
|
|
KG5 is a dual allosteric inhibitor of PDGFRβ and B-Raf with a Kd of 520 nM and 300 nM for PDGFRβ and PDGFRα. KG5 inhibits FLT3, KIT, and c-Raf with anticancer an...
|
